Holen Sie sich die Stockscreener-App
0.587
6.53%
-0.041
Handel nachbörslich:
.57
-0.017
-2.90%
Schlusskurs vom Vortag:
$0.628
Offen:
$0.6
24-Stunden-Volumen:
94,475
Relative Volume:
0.15
Marktkapitalisierung:
$19.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-6.6553
EPS:
-0.0882
Netto-Cashflow:
-
1W Leistung:
-16.14%
1M Leistung:
-5.22%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.55
$0.6325
1-Wochen-Bereich:
$0.55
$0.675
52-Wochen-Spanne:
$0.55
$19.51
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Firmenname
Jupiter Neurosciences Inc
Sektor
Branche
Telefon
(561) 406-6154
Adresse
1001 NORTH US HWY 1, JUPITER
Vergleichen Sie JUNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.587 | 19.43M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com South Africa
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment - Stock Titan
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Partners With Zina Biopharmaceuticals To Launch Phase 2a Parkinson's Trial - Nasdaq
Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn
Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn
US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jupiter Neurosciences refocuses on NLRP3 inflammasome By Investing.com - Investing.com South Africa
Jupiter Neurosciences refocuses on NLRP3 inflammasome - Investing.com India
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - GlobeNewswire
Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials - TipRanks
Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):